- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07943065
A Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke Patients (Crypto PulseON)
To evaluate the usability of the Pulse ON wearable device in patients with cryptogenic stroke/TIA
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The research project aims to evaluate the usability of a new device for detecting heart rhythm disturbances, especially atrial fibrillation (AF) in people who have had a stroke or mini-stroke (transient ischaemic attack [TIA]) of unknown cause (cryptogenic stroke). AF can be a major cause of disabling strokes and AF-related stroke risk is significantly reduced by starting specific blood thinners called anticoagulants.
Stroke is a major public health concern worldwide, with approximately 100,000 cases annually in the UK alone, making it a leading cause of death and disability. Around 38,000 stroke-related deaths occur each year, and many survivors experience significant long-term impairment. The vast majority (~90%) are ischaemic strokes, yet in 20-40% of cases, no definitive underlying cause is identified, despite extensive evaluation. These cryptogenic stroke cases remain a diagnostic challenge. Cryptogenic strokes are more common in younger stroke patients (<60 years) but can affect all age groups.
AF is the most common arrhythmia and a well-established cause of ischaemic stroke, responsible for 15-30% of cases. However, in cryptogenic stroke, AF often goes undiagnosed because it can come and go (i.e. is paroxysmal) and can be asymptomatic in nature, with episodes that can last for short periods of time but carry high risk of stroke. Early and accurate diagnosis of AF is crucial, as clinical trials have demonstrated the efficacy of oral anticoagulation in significantly reducing stroke risk. Thus, identifying AF in cryptogenic stroke patients can directly impact management by shifting treatment towards anticoagulation.
Background. Detecting AF in cryptogenic stroke is a major challenge and many methods fail to capture episodes of AF that come and go (paroxysmal). Conventional AF detection methods, such as in-hospital cardiac monitoring, serial ECGs, Holter monitors, external event recorders, wearable devices and implantable loop recorders (ILRs), vary in effectiveness. ILRs are small devices (the size of a pen-lid) implanted under the skin of the left chest wall and have a battery life of around three years. They have demonstrated superior diagnostic sensitivity, as highlighted in the CRYSTAL-AF trial, which showed their advantage over standard monitoring in cryptogenic stroke (AF detection rate of 12.4% for ILRs vs 2% for standard monitoring at 12 months). However, ILRs are invasive (which comes with its own procedure-related risks), costly, and may not be suitable for all patients.2 We want to evaluate a different type of AF detection device (the PulseON Arrhythmia Monitor System) that is not currently used in standard care, one that's wrist worn and non-invasive.
Proposed trial We propose a single centre, single arm feasibility pilot study designed to evaluate how practical and user friendly it is for participants to use the PulseON Arrhythmia Monitor System for detecting AF in addition to their normal standard of care. The study will explore whether participants can wear the device as intended, respond to alerts and successfully carry out ECG recordings using the system, whilst capturing their user experience and having their heart tracings closely monitored by health care professionals.
Trial population At UHCW NHS Trust, we manage approximately 1,400 strokes annually (with 350 classified as cryptogenic), many of whom will need to be monitored for AF. While most patients undergo Holter monitoring for AF, a smaller subset receive ILRs but their use is limited due their cost and invasive nature. The introduction of this PulseON device could significantly enhance AF detection, improving patient outcomes, be more cost-effective and optimise resource utilisation within our hospital and the broader NHS. We plan to evaluate whether cardiac monitoring with the PulseON system is feasible in patients with cryptogenic stroke/TIA. This evaluation project may inform wider research into this device and potential NHS implementation.
Treatment / Intervention We aim to recruit twelve patients who have experienced a cryptogenic ischaemic stroke or TIA within the past six months for this project. All patients who participate in the project will receive conventional standard of care investigations (Holter monitoring or ILR) in addition to the PulseON Arrhythmia monitoring system. The data collected will include experience of device usability via an MS forms questionnaire and a follow-up patient interview, baseline demographics, usability data and any newly detected arrhythmia observed from the heart tracing data, in particular AF (defined as an episode of AF lasting >30seconds). Any arrhythmia documented from the PulseON device will be uploaded and stored in an encrypted and secure cloud-based server.
Participants heart tracing data will be collected and reviewed by a suitably qualified healthcare professional within the study team (primarily the Principal Investigator).The reviewer will assess any detected cardiac events to determine their clinical significance and, when appropriate, will escalate relevant findings to the participant's clinical care team. This process ensures that any new or emerging information arising from the study is used to support and inform the provision of standard clinical care for participants.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Andrew White
- Numéro de téléphone: 02476968582
- E-mail: andrew.white@uhcw.nhs.uk
Lieux d'étude
-
-
-
Coventry, Royaume-Uni, CV2 2DX
- Recrutement
- University Hospital Coventry & Warwickshire NHS Trust
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients diagnosed with cryptogenic stroke/TIA
La description
Inclusion Criteria:
- Adult patients (>18yrs old) diagnosed with cryptogenic stroke / TIA
- Baseline electrocardiogram (ECG), Holter monitor and echocardiogram as part of the standard of care cardiac work-up in the diagnosis of cryptogenic stroke
Exclusion Criteria:
- Patients unwilling or unable to wear the PulseON arrhythmia detection device.
- Known pre-existing AF or atrial arrhythmia diagnosis.
- Participants without capacity will be excluded from this study.
- Participants who are pregnant will be excluded from this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Usability & Feasibility of PulseON wearable device
Délai: 1 month minimum
|
We will collect patient questionnaires and perform patient interviews to gather data on the PulseON device for usability and feasibility data. Formal feedback from health professionals who follow up the trial participants via the PulseON arrhythmia monitoring system online will be obtained. |
1 month minimum
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The prevalence of AF in people who have had cryptogenic ischaemic stroke or TIA.
Délai: 1 month
|
The ability of Pulse ON in detecting AF on ECG and how it differs from the standard of care (ECG, Holter monitoring or ILR) |
1 month
|
|
Baseline characteristics of cohort
Délai: 1 month
|
Baseline demographic and clinical characteristics |
1 month
|
Collaborateurs et enquêteurs
Les enquêteurs
- Directeur d'études: Faizel Osman, University Hospital Coventry & Warwickshire
- Chercheur principal: Ven G Lim, University Hospital Coventry & Warwickshire
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles cérébrovasculaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladies cardiaques
- Arythmies cardiaques
- Accident vasculaire cérébral
- Conditions pathologiques, signes et symptômes
- AVC ischémique
- Fibrillation auriculaire
Autres numéros d'identification d'étude
- FO658425
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .